Switzerland's Galenica AG's 2025 sales rise on wholesale expansion, pharmacy growth

Galenica AG

22/01/2026 05:49

Overview

Swiss healthcare firm's 2025 sales rose 5.5% to CHF 4.14 bln, driven by broad-based growth

Company confirmed 10-12% EBIT growth guidance for 2025

New Diagnostics area contributed 1% to sales growth

Outlook

Galenica confirms 10-12% EBIT increase for 2025

Company expects dividend to match or exceed last year's level

Galenica adjusts sales reporting for strategic transparency

Result Drivers

PHARMACY GROWTH - Strong demand for prescription medicines and dietary supplements drove pharmacy business growth

DIAGNOSTICS CONTRIBUTION - New Diagnostics area added 1% to sales growth

WHOLESALE EXPANSION - Continuous growth in wholesale supported overall sales increase

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
CHF 40.70 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Galenica AG is CHF87.50, about 8.9% below its January 21 closing price of CHF96.10

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nEQ9WWy7La

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)